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Type 2 diabetes mellitus is 
characterized by insulin resistance of 
peripheral tissues and dysfunction of 
pancreatic β-cells.  Furthermore, the number 
of pancreatic β-cells decreases as a 
secondary effect of advanced type 2 diabetes, 
although molecular mechanism has not been 
elucidated.  Recently, it has been shown that 
hyperglycemic conditions induce the 
expression of cyclooxygenase-2 (COX-2) in 
pancreatic islets and increase the 
downstream product prostaglandin E2 
(PGE2).  To investigate whether high 
glucose-induced PGE2 has an adverse effect 
on pancreatic β-cells, we generated 
transgenic mice (RIP-C2mE) that express 
COX-2 and microsomal prostaglandin E 
synthase-1 (mPGES-1) in their β-cells using 
the rat insulin-2 gene promoter (RIP).  The 
homozygous RIP-C2mE (Tg/Tg) mice showed 
severe hyperglycemia from 6 weeks of age.  
Although the heterozygous RIP-C2mE (Tg/−) 
mice showed normal blood glucose levels 
throughout their lifetime, this level increased 
significantly compared with that of wild-type 
mice when glucose was loaded.  The relative 
number of β-cells to the total islet cell 
number was reduced to 54% and 14% in the 
RIP-C2mE (Tg/−) and (Tg/Tg) mice, 
respectively, whereas that in the wild-type 
mice was 84%.  Importantly, the 
proliferation rate in the islets of the 
RIP-C2mE (Tg/Tg) mice at four weeks of age 
decreased significantly in comparison to that 
in the wild-type mice.  Because β-cells 
replicate not only during the postnatal 
period but also in the adult pancreas at a 
basal level, it is possible that increased PGE2 
signaling thus contributes to the reduction of 
the pancreatic β-cell mass through inhibition 
of proliferation, thereby aggravating 
diabetes further. 
 
Type 2 diabetes mellitus is characterized 
by the insensitivity of the peripheral tissues to 
insulin and the reduced function of the 
pancreatic β-cells.  It has been suggested that 
chronic hyperglycemia impairs β-cell function 
as a secondary adverse effect of diabetes (1).  
Furthermore, the β-cell mass in pancreatic islets 
is reduced significantly in type 2 diabetes 
patients (2,3,4).  In type 1 diabetes, a 
complexed autoimmune disease, an 
inflammatory cytokine IL-1β is an important 
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mediator in the impaired function and 
destruction of pancreatic β-cells (5).  For 
example, the treatment of isolated islets with 
IL-1 inhibits insulin secretion, and this is 
followed by islet destruction (6).  Moreover, 
adenoviral transduction of the IL-1 receptor 
antagonist protein into the islets protects against 
the IL-1β-induced dysfunction (7).  On the 
other hand, the long-term exposure of islets to 
high glucose conditions has been shown to 
result in the induction of IL-1β, followed by 
β-cell apoptosis (8).  This high glucose-induced 
β-cell destruction is prevented by treating the 
islets with an IL-1 receptor antagonist.  
Accordingly, it is possible that IL-1β plays a 
pivotal role in type 2 diabetes as well. 
Recently, it has been reported that high 
glucose conditions induce the expression of 
cyclooxygenase-2 (COX-2) in pancreatic islets 
with an increase of the downstream product 
prostaglandin E2 (PGE2) (9,10).  COX-2 
expression has also been detected in the 
pancreatic islets of db/db mice, a mouse model 
for type 2 diabetes mellitus (10).  COX-2 is a 
rate-limiting enzyme for prostanoid 
biosynthesis and plays various roles in 
physiological and pathological conditions such 
as reproduction, inflammation and 
tumorigenesis (11).  Although conflicting 
results have been reported, several studies 
indicate that the COX-2 pathway contributes to 
the pathogenesis of type 1 diabetes.  For 
example, IL-1β – a cytokine responsible for 
type 1 diabetes – induces COX-2 expression 
and PGE2 production in pancreatic islets (12).  
IL-1β-induced β-cell dysfunction is suppressed 
by the treatment of the islets with COX-2 
inhibitors (13).  Moreover, the destruction of 
the pancreatic β-cells in streptozotocin 
(STZ)-treated mice was inhibited by treatment 
with a COX-2 selective inhibitor, NS-398 (14).  
Therefore, it is possible that the 
hyperglycemia-induced production of IL-1β in 
the islets of type 2 diabetes causes the 
dysfunction and destruction of β-cells through 
further induction of the COX-2 pathway. 
In order to investigate the genetic 
mechanism of PGE2 signaling in pancreatic 
islets, we constructed transgenic mice that 
expressed COX-2 and microsomal 
prostaglandin E synthase-1 (mPGES-1) in their 
pancreatic β-cells by using the rat insulin-2 
gene promoter (RIP).  The inducible enzyme 
mPGES-1 catalyzes the conversion of PGH2 to 
PGE2, and appears to be functionally coupled 
with COX-2 (15).  In this study, we provide 
genetic evidence that increased PGE2 signaling 





Transgenic Mice – The RIP fragment (704 bp; 
nucleotide position, -695 to +8 of the rat 
insulin-2 gene) was amplified by PCR using rat 
genomic DNA and the following primers: 
5′-GGGATCCCCCAACCACT-3′ and 
5′-TTAGGGCTGGGGGTTACTGAA-3′.  After 
confirming the nucleotide sequences, the RIP 
fragment was subcloned into both expression 
vectors of COX-2 and mPGES-1 at the 5′ 
position in the same orientation as that of 
cDNAs.  Both expression vectors contained RIP, 
a synthetic chimeric intron excised from pCI 
(Promega, La Jolla, CA), cDNA for mouse 
COX-2 or mPGES-1, and a SV40 poly(A) 
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cassette (Fig. 1A).  Mouse COX-2 and 
mPGES-1 cDNAs were cloned by RT-PCR as 
previously described (16). The transcription unit 
was excised from each expression vector, 
purified, and co-microinjected into fertilized 
eggs from a cross between F1 (C3H and 
C57BL/6) hybrid females and C57BL/6 males.  
We obtained 14 founder mice that carried both 
the COX-2 and mPGES-1 transgenes.  Among 
the F1 progenies of these 14 lines, two lines 
(RIP-C2mE #8 and RIP-C2mE #9) showed high 
amounts of both COX-2 and mPGES-1 mRNAs 
in their pancreatic tissues.  These two transgenic 
lines showed essentially the same phenotypes.  
N2-backcrossed transgenic mice with C57BL/6 
were intercrossed to generate homozygous 
RIP-C2mE (Tg/Tg) and heterozygous 
RIP-C2mE (Tg/−) mice.  Backcrossing was 
performed using wild-type C57BL/6 mice.  
Mice of the N2F1 generation were used for the 
experiments.  Littermate wild-type mice were 
used as controls for the experiments.  
Genotyping was performed by genomic PCR 








Homozygotes were identified by increased band 
intensities of the genomic PCR products in 
comparison to those of the heterozygotes. 
Pancreatic Islet Isolation – Pancreata injected 
with 0.2% Collagenase Type I (Invitrogen, 
Carlsbad, CA) in Hank’s buffered saline 
solution via the bile duct were collected and 
incubated for 20 min at 370C.  After digestion, 
islets were then hand picked using a dissecting 
microscope. 
RT-PCR – Total RNA was extracted from the 
isolated islets using ISOGEN (Nippon Gene, 
Tokyo, Japan).  The extracted RNA was reverse 
transcribed and PCR amplified.  The primer sets 
used for genotyping were also used for RT-PCR 
analyses of COX-2 and mPGES-1.  GAPDH 
was used as an internal control. 
Measurement of Pancreatic PGE2 Level – The 
PGE2 levels were measured at SRL (SRL Inc., 
Tokyo, Japan) using 6 RIP-C2mE (Tg/−) and 6 
wild-type mice at 20 weeks of age, and 4 
RIP-C2mE (Tg/−) and 4 RIP-C2mE (Tg/ Tg) 
mice at 3 weeks of age.  Briefly, the pancreata 
were homogenized in a lysis buffer, and PGE2 
was extracted with ethanol.  The PGE2 levels 
were measured using Prostaglandin E2 [125I] 
RIA Kit (Perking Elmer Life Science, Boston, 
MA).  According to the manufacturer’s 
instruction manual, the cross reactivity of this 
kit is as follows: PGE2 (100%), PGF2α (0.9%), 
PGD2 (0.3%), 6-keto-PGF1α (1%) and 
thromboxane B2 (0.01%).  The islet PGE2 levels 
of the RIP-C2mE (Tg/ Tg) mice relative to 
(Tg/−) mice at 3 weeks of age was calculated 
using the ratio of the islet area in the pancreas.  
To determine the ratio of the islet area in the 
RIP-C2mE (Tg/−) and (Tg/ Tg) mice, five 
sections per pancreas of each genotype were 
scanned using an ImageJ program (NIH) and 
then the islet area was quantified versus the 
total pancreas area. 
Measurement of Blood Glucose, Plasma Insulin, 
and Plasma Glucagon Levels – The blood 
glucose levels were measured using Glutest 
AceR (Sanwa Chemical, Nagoya, Japan).  For 
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chronological observation, the blood glucose 
level was examined when the mice were 3, 6, 9, 
and 12 weeks of age.  In this experiment, 6 
wild-type, 12 RIP-C2mE (Tg/−), and 11 
RIP-C2mE (Tg/Tg) mice were used.  The 
plasma insulin levels were examined through 
use of the High-Sensitive Insulin Measurement 
Kit that is based on an ELISA test (Morinaga, 
Yokohama, Japan) at 0 and 20 min of the 
glucose tolerance test.  The plasma glucagon 
levels were measured by a radioimmunoassay 
which uses the Glucagon Kit Daiichi II at SRL 
(Tokyo, Japan), with 10 wild-type and 4 
RIP-C2mE (Tg/Tg) mice. 
Glucose Tolerance Test – The mice were fasted 
for 14 hours following an i.p. injection of 
glucose (1 g/kg body weight).  Blood samples 
were obtained from a tail vein at 10, 20, 30, 60, 
and 120 min after the glucose injection.  The 
blood glucose and plasma insulin levels were 
measured as described.  In the glucose tolerance 
test, 7 wild-type and 8 RIP-C2mE (Tg/−) mice 
at 50 weeks of age were used. 
Histopathology and Immunohistochemistry – 
Pancreatic tissues of the mice were fixed in 4% 
paraformaldehyde, embedded, and sectioned at 
a 4 µm-thickness.  These sections were stained 
with H & E and were processed further for 
immunostaining.  Rabbit polyclonal antibody 
for insulin (Progen Biotechnik, Heidelberg, 
Germany) and sheep polyclonal antibody for 
glucagon (Biogenesis, England, UK) were used 
as the primary antibody for an 
immunohistochemistry to detect β-cells and α 
cells, respectively.  Rat monoclonal antibodies 
for CD3ε (BD, Franklin Lakes, NJ), F4/80 
(Serotec, Oxford, UK) and Gr-1/Ly-6G (BD, 
San Jose, CA) were used as the primary 
antibodies to detect T cells, macrophages and 
neutrophils, respectively.  Staining signals were 
visualized using the Vectorstain Elite kit 
(Vector, Burlingame, CA).  Alexa Fluor 594 
donkey anti-sheep IgG or Alexa Fluor 488 
donkey anti-rabbit IgG (Molecular Probes, 
Eugene, OR) was used as the secondary 
antibody. 
Apoptosis Analysis – The pancreatic tissues of 
the mice at 4 weeks of age were fixed in 4% 
paraformaldehyde, embedded, and sectioned at 
a 4 µm-thickness.  Apoptosis was determined 
based upon the TUNEL method, which uses the 
ApopTag Peroxidase in situ Apoptosis 
Detection Kit (Chemicon, Temecula, CA) 
according to the manufacturer’s protocol.   
Cell Proliferation Analysis – Mice were injected 
i.p. with 1 ml of a BrdU solution (1 mg/ml).  At 
3 hours post-injection, pancreatic tissues were 
fixed in 4% paraformaldehyde, embedded, and 
sectioned at a 4 µm-thickness.  The sections 
were immunostained with an anti-BrdU 
antibody using the BrdU In-Situ Detection Kit 
(BD, San Jose, CA).  The number of 
BrdU-labeled cells and total number of islet 
cells were scored from 10 islets and a mean 
BrdU labeling index was calculated. 
Scoring the Ratio of α-Cells and β-Cells in the 
Pancreatic Islets – At least 6 nonoverlapping 
fields of the fluorescence-immunostained 
sections were photographed (total number of 
islets > 12), and the number of 
glucagon-positive α-cells and insulin-positive 
β-cells were scored.  The ratio of α-cells and 
β-cells in the islet was calculated by dividing 
each number with the total number of islet cells.  
The total cell number in each islet was scored 
using the same sections under a differential 
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interference microscope, DM5000B (Leica 
Microsystems, Wetzler, Germany).   
Statistical Analysis – Statistical analyses were 
carried out using the unpaired Student’s t test, 





In order to investigate the effects of PGE2 
on the pancreatic β-cells in mice, we generated 
transgenic (RIP-C2mE) mice expressing both 
COX-2 and mPGES-1 by co-microinjection of 
the two expression vectors (Fig. 1A).  We used 
RIP to target the β-cells in the pancreatic islets.  
To increase the expression level of the 
transgenes, we introduced a synthetic intron 
between the RIP and cDNAs for COX-2 and 
mPGES-1 (16).  Two transgenic lines 
(RIP-C2mE#8 and RIP-C2mE#9) essentially 
exhibited the same phenotype (data not shown).  
Accordingly, we present the results with 
RIP-C2mE#8 (hereafter referred to as 
RIP-C2mE).  We detected high amounts of 
mRNA of COX-2 and mPGES-1 by RT-PCR in 
the isolated islets from the RIP-C2mE (Tg/−) 
mice, while the expression of both genes was 
found in the wild-type islets at a basal level (Fig. 
1B). We consistently found strong 
immunostaining signals for COX-2 and 
mPGES-1 in the pancreatic islets of the 
RIP-C2mE (Tg/−) mice compared with those of 
the wild-type mice (Fig. 1C).  As shown in Fig. 
1D, pancreatic PGE2 levels at 20 weeks of age 
increased significantly in the RIP-C2mE (Tg/−) 
mice (10.9 ± 2.2 pg/mg) in comparison to that 
in the wild-type mice (4.2 ± 0.5 pg/mg), 
indicating that the simultaneous transgenic 
expression of COX-2 and mPGES-1 produced 
PGE2 in vivo. 
The blood glucose level in the RIP-C2mE 
(Tg/−) mice did not differ from that in the 
wild-type mice at 4 months of age (data not 
shown).  To examine whether increased PGE2 
affects β-cell function under hyperglycemic 
conditions, we carried out the glucose tolerance 
test using fasted RIP-C2mE (Tg/−) mice.  As 
shown in Fig. 2A, the RIP-C2mE (Tg/−) mice 
showed a significant increase in the blood 
glucose level in comparison to that in the 
wild-type mice from 10 to 60 min after the 
glucose injection.  In the wild-type mice, the 
plasma insulin level at 20 min post-glucose 
injection increased significantly in comparison 
to that at 0 min (Fig. 2B).  However, the plasma 
insulin level in the RIP-C2mE (Tg/−) mice at 20 
min was significantly lower than that in the 
wild-type mice, although it had increased a 1.3 
fold of the basal level at 0 min.  These results 
indicate that increased PGE2 in the pancreatic 
β-cells causes impaired insulin secretion under 
hyperglycemic conditions. 
To further investigate the role of PGE2 
signaling in pancreatic β-cells, we intercrossed 
heterozygous RIP-C2mE (Tg/−) mice to 
generate homozygous RIP-C2mE (Tg/Tg) mice 
that carried double the copy number of each 
transgene.  The mean PGE2 level in the 
pancreas of the RIP-C2mE (Tg/Tg) mouse at 3 
weeks of age was higher than that in the 
pancreas of the RIP-C2mE (Tg/−) mice, 
although it was not significant (Fig. 3A).  
However, the ratio of islet area in the pancreas 
of the RIP-C2mE (Tg/Tg) mice was lower than 
that in the RIP-C2mE (Tg/−) mice (0.39% and 
0.59% of the total pancreas in the Tg/Tg and 
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Tg/− mice, respectively).  Consequently, the 
relative islet PGE2 level in the RIP-C2mE 
(Tg/Tg) mice was a 1.9-fold higher than that in 
the RIP-C2mE (Tg/−) mice (Fig. 3B).  We 
determined the blood glucose level 
chronologically when the mice were 3, 6, 9, and 
12 weeks of age (Fig. 3C).  The blood glucose 
levels in the RIP-C2mE (Tg/−) mice were 
normal at all examined ages; this was consistent 
with the results of the blood glucose tolerance 
test.  However, the homozygous RIP-C2mE 
(Tg/Tg) mice showed a significant increase in 
the blood glucose levels from 6 weeks of age, 
thus suggesting that insulin secretion was 
inhibited by PGE2 signaling in a 
dose-dependent manner.  Importantly, the blood 
glucose level of the RIP-C2mE (Tg/Tg) mice at 
3 weeks of age was at the normal level, 
indicating that the dysfunction of the pancreatic 
β-cells was not caused by the congenital 
anomaly of the pancreatic islets. 
We then examined the pancreatic β-cells 
by fluorescence immunohistochemistry using 
pancreatic tissue of the respective mouse 
genotypes at 16 weeks of age.  In the wild-type 
mice, the insulin-positive β-cells predominated 
the pancreatic islets, whereas the 
glucagon-producing α-cells were found 
scattered in the marginal regions of the islets 
(Fig. 4A).  In the heterozygous RIP-C2mE 
(Tg/−) mice, the number of β-cells decreased 
compared with that in the wild-type mice, while 
the α-cell population increased slightly (Fig. 
4B).  In sharp contrast to the wild-type mice, 
α-cells predominated the RIP-C2mE (Tg/Tg) 
mouse islets, and the β-cells were sparsely 
distributed in the center of the islets (Fig. 4C).  
The mean relative ratio of β-cells to the total 
number of islet cells was 84%, 54%, and 14% 
in the wild-type, RIP-C2mE (Tg/−), and (Tg/Tg) 
mice, respectively (Fig. 4D).  In contrast, the 
mean ratio of α-cells increased inversely with 
the RIP-C2mE (Tg/−) and (Tg/Tg) mice (Fig. 
4E).  However, the mean plasma glucagon level 
in the RIP-C2mE (Tg/Tg) mice stayed at similar 
level to that found in the wild-type mice (97.0 ± 
4.4 pg/ml and 101.3 ± 9.2 pg/ml in the 
wild-type and RIP-C2mE (Tg/Tg) mice, 
respectively). These results collectively indicate 
that an increase in the PGE2 level causes a 
diabetic phenotype through a decrease in the 
number of pancreatic β-cells.   
In order to rule out the possibility that 
PGE2 signaling impairs the development of the 
pancreatic islets, we carried out fluorescence 
immunohistochemistry with mice at 3 weeks of 
age.  The number of pancreatic β-cells in the 
wild-type mice at 3 weeks of age was less than 
that found at 16 weeks of age (Fig. 5A and C; 
and Fig. 4A and D).  It is possible that the 
number of β-cells is still increasing at 3 weeks 
of age because β-cells replicate during the 
postnatal period to increase the β-cell mass to 
that of an adult level (17).  Notably, the number 
of β-cells in the homozygous RIP-C2mE 
(Tg/Tg) mice was at the same level as that in the 
wild-type mice (Fig. 5B and C).  Consistently, 
the number of α-cells in the RIP-C2mE (Tg/Tg) 
mice also demonstrated the same level as that of 
the wild-type mice (Fig. 5D).  These results, 
taken together, indicate that increased PGE2 
signaling causes a decrease in the number of 
β-cells after weaning.   
To further investigate the mechanism of 
β-cell destruction, we examined apoptosis in the 
pancreatic islets at 4 weeks of age by the 
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TUNEL method.  However, we did not find any 
apoptotic cells in the islets of the RIP-C2mE 
(Tg/Tg) mice or the wild-type mice (data not 
shown).  We thus examined the cell 
proliferation rate by BrdU incorporation at 4 
weeks of age.  Although the proliferation rate in 
the islets of the RIP-C2mE (Tg/−) mice was 
almost the same as that in the wild-type mice 
(Fig. 5E, F and H), it was decreased 
significantly in the RIP-C2mE (Tg/Tg) mice 
(Fig. 5G and H), thus suggesting that PGE2 
signaling inhibits the proliferation of β-cells.   
It has been suggested that the COX-2 
pathway is involved in the development of the 
autoimmune disease, type 1 diabetes (12,13,14).  
It was thus possible that the increased PGE2 
signaling had induced a host inflammatory or 
immune response in the pancreatic islets, thus 
causing further β-cell destruction.  To assess 
this possibility, we histologically examined the 
islets of the homozygous RIP-C2mE (Tg/Tg) 
mice.  Although the islets of the (Tg/Tg) mice 
appeared to be smaller than those of the 
wild-type mice, no inflammatory cell 
infiltration was observed around either of the 
islets in the RIP-C2mE (Tg/Tg) and wild-type 
mice (Fig. 6A and B).  Furthermore, we did not 
find any infiltration of T lymphocytes (CD3), 
macrophages (F4/80) or neutrophils (Gr-1) 
around islets of the RIP-C2mE (Tg/Tg) mice at 
both 4 and 16 weeks of age (Fig. 6C, D, E, and 
F).  Therefore, these results indicate that an 
inflammatory or immune response is not 





In advanced type 2 diabetes mellitus, the 
pancreatic β-cell mass reduces through 
oxidative stress-related damage or increased 
apoptosis, resulting in secondary adverse effects 
upon β-cells (2,3,4).  It has been demonstrated 
that hyperglycemic conditions induce the IL-1β, 
which is responsible for the dysfunction and 
destruction of pancreatic β-cells (8).  Recently, 
it has been shown that COX-2 expression is also 
induced in the pancreatic islets under high 
glucose conditions (9,10).  Moreover, IL-1β 
signaling stimulates COX-2 induction and PGE2 
production in pancreatic islets (12,13,18).  
These results, taken together, suggest that 
COX-2 plays a role in the IL-1β-induced β-cell 
damage.  Here, we demonstrate that the 
expression of COX-2 and mPGES-1, which 
leads to an increase in islet PGE2 production, 
causes a significant decrease in the number of 
pancreatic β-cells.  These results provide the 
first genetic evidence for the causal role of the 
COX-2/PGE2 pathway in β-cell destruction.  
Importantly, after doubling the number of 
copies of COX-2 and mPGES-1 by generating 
homozygous RIP-C2mE (Tg/Tg) mice, there 
was severe reduction of the β-cell mass with a 
significant increase in the blood glucose level 
when compared with the heterozygous 
RIP-C2mE (Tg/−) mice.  Therefore, it is 
possible that the induction level of COX-2 and 
PGE2 is correlated with the severity of the 
pancreatic β-cell damage in type 2 diabetes. 
Although the number of α-cells was 
elevated in the adult RIP-C2mE (Tg/Tg) mice, 
the plasma glucagon level was not increased.  
Thus, increased blood glucose is caused by the 
reduced number of β-cells and not by the 
increased number of α-cells.  We herein found a 
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significant decrease in the cell proliferation rate 
in the RIP-C2mE (Tg/Tg) mouse islets at 4 
weeks of age.  Because β-cells replicate during 
the postnatal period (17), it is possible that these 
proliferating cells are β-cells, and that PGE2 
signaling inhibits this β-cell proliferation.  The 
number of β-cells in the normal adult islets is 
regulated by a balance between proliferation 
and apoptosis (19).  It has been estimated that it 
takes 3 months for the renewal of 50% of the 
pancreatic β-cells (20) and 9 months for the 
renewal of 98% (21).  Accordingly, it is 
conceivable that increased PGE2 signaling 
suppresses β-cell proliferation in the adult islets, 
resulting in gradual reduction of the β-cell 
mass.   
Recently, it has been demonstrated that 
the expression of p27Kip1 plays a key role in 
regulation of the pancreatic β-cell mass, and 
that deletion of the gene encoding p27Kip1 in the 
type 2 diabetes model (db/db mice) prevents 
β-cell destruction (22).  Therefore, it is 
important to investigate the underlying 
relationship between PGE2 and p27Kip1 in β-cell 
destruction. 
Type 1 diabetes mellitus is characterized 
by β-cell destruction due to autoimmune 
responses, which are critically dependent upon 
the interaction between antigen-presenting cells 
and T cells.  Because we did not observe 
inflammatory or immune cell infiltration around 
the pancreatic islets in the RIP-C2mE mice, we 
concluded that the inhibition of β-cell 
proliferation in our mouse model is not caused 
by host immune responses.  However, IL-1β 
signaling also plays an important role in the 
β-cell destruction of type 1 diabetes (23).  
Furthermore, the IL-1β-induced inhibition of 
insulin secretion is suppressed by COX-2 
inhibitors; this is reconfirmed by exogenous 
PGE2 stimulation (13).  Therefore, it is possible 
that PGE2 plays some role as a downstream 
mediator of the IL-1β pathway during β-cell 
destruction in type 1 diabetes as well. 
It has been suggested that chronic 
inflammation plays an etiological role in type 2 
diabetes (24), and that chronic activation of the 
immune system causes a decrease in insulin 
sensitivity, which may contribute to the 
pathogenesis of type 2 diabetes (25).  The 
present results suggest that chronic 
inflammatory responses are involved in the 
decrease of pancreatic β-cells via the induction 
of COX-2 and PGE2, which leads to an 
increased susceptibility to type 2 diabetes.  
Moreover, an epidemiological study has 
indicated the association of the promoter variant 
of the COX-2 gene with type 2 diabetes in Pima 
Indians (26).  Although COX-2 is an inducible 
enzyme in most tissues, it has shown to be 
expressed constitutively in pancreatic islets (27).  
Therefore, it is probable that an increase in the 
basal level of COX-2 expression, caused by a 
promoter polymorphism, enhances the 
susceptibility to type 2 diabetes via the 
suppression of the renewing capabilities of islet 
β-cells.  It is therefore possible that the 
blockade of PGE2 receptors or the inhibition of 
mPGES-1 is an effective therapeutic strategy 
against β-cell destruction in type 2 as well as 
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Fig. 1. Generation of RIP-C2mE transgenic mice.  A, Schematic construction of transgenic vectors for 
COX-2 (top) and mPGES-1 (bottom).  The synthetic chimeric intron is indicated by a V shape between 
the RIP and each cDNA fragment.  COX-2 and mPGES-1 cDNA fragments and SV40 poly(A) 
cassettes are indicated as gray and black boxes, respectively.  B, Representative RT-PCR for COX-2, 
mPGES-1 and GAPDH using the RNA prepared from isolated islets.  Tg, RIP-C2mE (Tg/−) mice; W, 
wild-type mice; M, molecular weight marker (λ DNA digested with EcoRI/HindIII).  C, 
Representative immunohistochemistry for COX-2 (top) and mPGES-1 (bottom) in the pancreatic islets 
of the wild-type (left) and RIP-C2mE (Tg/−) mice (right).  Bars, 100 µm.  D, The PGE2 levels 
compared to the total pancreatic weight are indicated for the wild-type and RIP-C2mE (Tg/−) mice as 
black and gray bars, respectively (mean ± SEM).  *, P < 0.05. 
 
Fig. 2. Blood glucose and plasma insulin levels of the RIP-C2mE (Tg/−) mice loaded with glucose 
(glucose tolerance test).  A, Blood glucose levels at 10, 20, 30, 60, 90 and 120 min after i.p. injection 
of glucose (1 g/kg body weight) in fasted mice.  Data for the wild-type and RIP-C2mE (Tg/−) mice are 
indicated as black squares and gray triangles, respectively (mean ± SEM).  *, P < 0.05 versus the 
wild-type level at the same age.  B, Plasma insulin levels at 0 and 20 min after i.p. injection of glucose 
(1 g/kg body weight).  Data for the wild-type and RIP-C2mE (Tg/−) mice are indicated in black and 
gray bars, respectively (mean ± SEM)  *, P < 0.05. 
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Fig. 3. PGE2 levels and chronological blood glucose in the RIP-C2mE (Tg/Tg) mice.  A, The PGE2 
levels to the total pancreatic weight are indicated for the RIP-C2mE (Tg/−) mice and RIP-C2mE (Tg/ 
Tg) mice as black and gray bars, respectively (mean ± SEM).  B, The relative islet PGE2 levels are 
indicated for the RIP-C2mE (Tg/−) mice and RIP-C2mE (Tg/ Tg) mice as black bars and grey bars, 
respectively (mean ± SEM).  *, P < 0.05.  C, Chronological blood glucose levels in the wild-type mice 
(black squares), RIP-C2mE (Tg/−) mice (open triangles), and RIP-C2mE (Tg/Tg) mice (closed circles) 
at 3, 6, 9, and 12 weeks of age (mean ± SEM).  *, P < 0.05 versus wild-type level at the same age. 
 
Fig. 4. Fluorescence immunostaining of the islets for insulin (β-cell; green) and glucagon (α-cell; red) 
at 16 weeks of age.  Representative results of two islets each for the wild-type mice (A), RIP-C2mE 
(Tg/−) mice (B), and RIP-C2mE (Tg/Tg) mice (C).  Bars, 100 µm.  The ratio of β-cells (D) and α-cells 
(E) to the total islet cells (mean ± SEM).  *, P < 0.05. 
 
Fig. 5. Fluorescence immunostaining of the pancreatic islets for insulin (β-cell; green) and glucagon 
(α-cell; red) at 3 weeks of age.  Representative results for three islets each for the wild-type mice (A) 
and RIP-C2mE (Tg/Tg) mice (B).  Bars in (A and B), 100 µm.  The ratio of β-cells (C) and α-cells (D) 
to the total islet cells (mean ± SEM).  Immunostaining for BrdU in the islets of the wild-type (E), 
RIP-C2mE (Tg/-) (F), and (Tg/Tg) (G) mice at 4 weeks of age.  Arrowheads indicate 
BrdU-incorporated cells.  Bars in (E-G), 50 µm.  H, BrdU labeling index per islet of the respective 
mouse genotypes (mean ± SEM).  *, P < 0.05. 
 
Fig. 6. Representative histological analyses of the pancreatic islets of the RIP-C2mE (Tg/Tg) mice.  A, 
Control islets from the wild-type mice (H & E).  B, RIP-C2mE (Tg/Tg) mice (H&E).  C, 
Immunostaining for the T cell marker CD3ε in the RIP-C2mE (Tg/Tg) mice.  D, Immunostaining for 
the macrophage-specific F4/80 in the RIP-C2mE (Tg/Tg) mice.  Arrows in (A-D) indicate islets.  E, 
Fluorescent immunostaining for Gr-1 (green) and DAPI (blue) in the RIP-C2mE (Tg/Tg) mice.  Arrow 
in (E) indicates Gr-1-positive neutrophil.  F, The same section of (E) observed with a phase contrast 
microscope.  Arrows in (F) indicate islets.  Tissue sections were prepared from mice at 16 weeks of 
age (A-D) and 4 weeks of age (E and F).  Bars, 100 µm. 
 






